Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Fagron N.V. Major Shareholding Notification 2013

Sep 24, 2013

3949_mrq_2013-09-24_1eb4a5fe-9edf-4bb0-9690-231e9ac132f0.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Waregem (Belgium) / Rotterdam (Netherlands)1 , 24 September 2013 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received a joint notification on 19 September 2013 from Alychlo NV and Marc Coucke concerning the acquisition or disposal of voting securities. The joint shareholding of Alychlo NV and Marc Coucke has fallen below the disclosure threshold of 10% through the disposal of voting securities. Alychlo NV is controlled by Marc Coucke.

Based on the denominator of 31,358,358 (total number of voting rights) and the relevant notifications that Arseus received, the shareholder structure as of 24 September 2013 is as follows:

Number of shares % of effective voting rights
EnHold NV 8,166,908 26.04%
Alychlo NV / Coucke 3,008,080 9.59%
BNP Paribas Investment Partners SA 1,609,182 5.13%
Arseus NV (treasury shares) 881,378 2.81%
Public 17,692,810 56.43%
Total 31,358,358 100.00%

The original notification forms are available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

1/2

For more information: Constantijn van Rietschoten Director of Corporate Communications +31 88 33 11 222 (Office) +31 6 53 69 15 85 (Mobile) [email protected]

This press release was sent out by Arseus NV and Arseus BV.

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.